
WALD Stock Forecast & Price Target
WALD Analyst Ratings
Bulls say
Waldencast is a company with strong potential for growth, with their Obagi skincare segment showing impressive growth in both their DTC channel and international market. However, their Milk Makeup segment has faced challenges, particularly in the international market, which may need to be addressed for overall growth. The ongoing SEC investigation and potential dilution from future securities offerings may also have an effect on the company's growth potential. Additionally, the reliance on one main distributor in the U.S. and potential supply chain pressures could also impact the business. Overall, while the company's brands have room for growth, investors should be aware of potential risks and uncertainties in the future.
Bears say
Waldencast is experiencing declining sales and profitability, with a lack of guidance for future years due to the ongoing strategic review and potential divestment of assets. Their main revenue driver, the Obagi Medical segment, may face headwinds from currency fluctuations and other industry-specific risks. The company's high level of debt and uncertainty around their future direction make it a risky investment.
This aggregate rating is based on analysts' research of Waldencast Acquisition Corp and is not a guaranteed prediction by Public.com or investment advice.
WALD Analyst Forecast & Price Prediction
Start investing in WALD
Order type
Buy in
Order amount
Est. shares
0 shares